GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (LSE:AVCT) » Definitions » Retained Earnings

Avacta Group (LSE:AVCT) Retained Earnings : £-85.75 Mil (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Avacta Group Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Avacta Group's retained earnings for the quarter that ended in Dec. 2023 was £-85.75 Mil.

Avacta Group's quarterly retained earnings declined from Dec. 2022 (£-66.00 Mil) to Jun. 2023 (£-76.22 Mil) and declined from Jun. 2023 (£-76.22 Mil) to Dec. 2023 (£-85.75 Mil).

Avacta Group's annual retained earnings declined from Dec. 2021 (£-34.09 Mil) to Dec. 2022 (£-66.00 Mil) and declined from Dec. 2022 (£-66.00 Mil) to Dec. 2023 (£-85.75 Mil).


Avacta Group Retained Earnings Historical Data

The historical data trend for Avacta Group's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avacta Group Retained Earnings Chart

Avacta Group Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.30 -12.86 -34.09 -66.00 -85.75

Avacta Group Semi-Annual Data
Jul13 Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.09 -39.74 -66.00 -76.22 -85.75

Avacta Group Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Avacta Group  (LSE:AVCT) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Avacta Group (LSE:AVCT) Business Description

Traded in Other Exchanges
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group (LSE:AVCT) Headlines

No Headlines